10-Q: Village Farms Reports Strong Q1 2026 Growth

Village Farms International Inc. announced a significant increase in Q1 2026 revenue, driven by a surge in international cannabis exports and improved gross margins.

Summary

• Village Farms International, Inc. reported a 27% increase in total revenue for the first quarter of 2026, reaching $50.2 million compared to $39.7 million in the same period of 2025.
• Net income attributable to shareholders was $2.9 million ($0.03 per basic share), a substantial improvement from a net loss of $6.7 million ($0.06 per basic share) in Q1 2025.
• Adjusted EBITDA from continuing operations more than doubled to $9.9 million from $4.5 million in the prior year.
• The company's cannabis segment saw revenue grow by 27%, with international exports increasing by 171% year-over-year.
• The company has realigned its reporting structure to a single 'Cannabis' segment.
• Facility upgrades have been completed at the Delta, British Columbia campus, making it the world's largest EU-GMP certified cannabis facility.
• Expansion projects in Delta, Canada, and the Netherlands are underway, expected to contribute to sales in late Q2 2026 and ramp up by the end of 2026, respectively.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, a return to profitability, and substantial improvements in key operational metrics like Adjusted EBITDA and gross margins.

Positives

• Revenue increased by 27% to $50.2 million in Q1 2026.
• Net income attributable to shareholders turned positive at $2.9 million, compared to a net loss of $6.7 million in Q1 2025.
• Adjusted EBITDA from continuing operations increased by 118% to $9.9 million.
• International export sales from Canada grew by 171% year-over-year to a record $14.6 million.
• The company maintained a top five market share position in Canada and the number one position in dried flower.
• Gross profit increased by 48% to $21.0 million.
• The company's Pure Sunfarms brand expanded its market share for the 15th consecutive month.
• The FCC Term Loan maturity was extended by four years to February 3, 2031, with a 50 basis point reduction in the interest rate margin.
• The Pure Sunfarms Secured Credit Facility was amended and extended, increasing loan commitments by C$15 million and extending maturities by one year to February 2029.
• The company believes it is poised to benefit from President Trump's Executive Order regarding cannabis rescheduling to Schedule III.

Negatives

• Sales for U.S. Cannabis decreased by 20% due to market saturation from unregulated hemp-derived products and changing state regulations.
• The company incurred $15.9 million in Canadian excise duties, representing 40% of gross Canadian Branded sales.
• Cash used in operating activities was $16.8 million, compared to $3.8 million used in the prior year's quarter, largely due to income tax payments.
• Cash, cash equivalents, and restricted cash decreased to $55.5 million from $86.3 million at the end of the previous year.

Risks

• Uncertainty regarding the legality and regulatory status of cannabis and cannabinoid (CBD) products in the United States.
• Risks related to the implementation and enforcement of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026.
• Risks relating to the integration of Balanced Health and Rose into the consolidated business.
• Risks relating to obtaining additional financing on acceptable terms, including dependence upon credit facilities and dilutive transactions.
• Potential difficulties in achieving and/or maintaining profitability.
• Variability of product pricing.
• Risks inherent in the cannabis, hemp, CBD, cannabinoids, and agricultural businesses.
• The company's market position and competitive position.
• The ability to leverage current business relationships for future business involving hemp and cannabinoids.
• The ability of Pure Sunfarms and Rose to cultivate and distribute cannabis in Canada as well as exports.
• Risks related to the start-up of international production at its Netherlands operations under Leli.
• Existing and new governmental regulations, including risks related to regulatory compliance and obtaining and maintaining licenses required under the Cannabis Act (Canada), the Criminal Code and other Acts.
• Legal and operational risks relating to the expected conversion of greenhouses to cannabis production in Canada and in the United States.
• Risks related to rules and regulations at the U.S. Federal (Food and Drug Administration and United States Department of Agriculture), state and municipal levels with respect to produce and hemp, cannabidiol-based products commercialization.
• Retail consolidation, technological advances, and other forms of competition.
• Transportation disruptions.
• Product liability and other potential litigation.
• Retention of key executives.
• Labor issues.
• Uninsured and underinsured losses.
• Vulnerability to rising energy costs.
• Inflationary effects on costs of cultivation and transportation.
• Recessionary effects on demand for products.
• Environmental, health and safety risks.
• Foreign exchange exposure.
• Risks associated with cross-border trade and the potential for tariffs and other trade restrictions.
• Difficulties in managing growth.
• Restrictive covenants under credit facilities.
• Natural catastrophes.
• Elevated interest rates.
• Tax risks.
• The company's limited operating history in the cannabis and cannabinoids industry.
• The limited operational history of the Delta RNG Project in the energy segment.
• The legal status of the cannabis business of Pure Sunfarms, Rose, and VFN and the hemp business of Balanced Health.

Future Outlook

The company expects to commence all operations at its Phase II facility in the Netherlands during Q2 2026 and ramp to full capacity by the end of 2026, which is expected to quintuple total Netherlands production. The Delta 2 greenhouse expansion in Canada is expected to begin contributing to sales late in the second quarter of 2026, with full expansion yielding an incremental 40 metric tonnes of annualized cannabis production by 2027. The company believes it is poised to benefit from potential U.S. cannabis rescheduling to Schedule III.

Management Comments

• The company's mission is to apply decades of innovation in intensive agriculture to lead a sustainable path forward for the global cannabis industry.
• Focus for Cannabis is to produce high quality cannabis, leveraging low-cost production to provide preferred products at an attractive price.
• International expansion is expected to enhance profitability and expand brand and experience into emerging legal cannabis markets.
• The company believes it operates the world's largest EU-GMP certified cannabis facility after recent upgrades.
• The company believes it is poised to benefit from President Trump's Executive Order, which, if the broader rescheduling is enacted as anticipated, would represent a consequential step in modernizing U.S. cannabis policy.

Industry Context

StockSavvy.ai notes that Village Farms International's Q1 2026 results reflect a strong performance in the international cannabis export market, a key growth area for the industry. The company's focus on low-cost, high-quality production and EU-GMP certification positions it well for global expansion, especially as regulatory landscapes evolve, such as the potential rescheduling of cannabis in the U.S.

Comparison to Industry Standards

• Village Farms' Pure Sunfarms brand holds the number one market share position in dried flower in Canada, indicating a leading position against domestic competitors.
• The company's international export sales to Europe, particularly Germany, are noted as being among the largest for medical cannabis, with strong cultivar rankings, suggesting a competitive advantage over other European suppliers.
• The company's achievement of EU-GMP certification for its Delta 3 facility, now considered the world's largest, sets a high standard for quality and compliance in international cannabis markets.
• The company's ability to surpass its targeted gross margin range for cannabis for the fourth consecutive quarter suggests operational efficiency that may be superior to some industry peers facing margin pressures.

Management Changes

Legal Proceedings

• The company is engaged in legal proceedings in the ordinary course of business, but none are considered material to the business.

Related Party Transactions

• The company leases its Rose office building from a former employee who also owns a minority interest in Rose. Payments for this lease were C$35 for Q1 2026 and C$36 for Q1 2025.
• A Transition Services Agreement and a Sales, Marketing & Distribution Agreement are in place with Village Fresh, a Vanguard subsidiary, for transition services and the distribution of tomatoes from VFCLP's British Columbia greenhouse facilities.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, return to profitability, and positive earnings per share.
• Employees: Potential for continued employment and growth within the expanding cannabis operations.
• Creditors: Improved financial health and extended debt maturities may provide increased confidence.
• Suppliers: Continued demand for inputs related to increased production and expansion projects.

Next Steps

• Commence all operations at the Phase II facility in the Netherlands during Q2 2026 and ramp to full capacity by the end of 2026.
• Begin contributing to sales from the Delta 2 greenhouse expansion in Canada in late Q2 2026, with full expansion expected by 2027.
• Continue to benefit from potential U.S. cannabis rescheduling to Schedule III, with an administrative hearing process expected to commence on June 29, 2026.
• Identify a permanent replacement for the Chief Financial Officer and transition responsibilities.

Key Dates

Recommendation

The company has demonstrated significant operational improvements, including substantial revenue growth, a return to profitability, and expansion of international markets. The positive outlook for U.S. cannabis rescheduling and ongoing capacity expansions further support a strong growth trajectory. The improved financial metrics and strategic initiatives suggest a compelling investment opportunity.

Keywords

Village Farms International, VFF, Cannabis, Q1 2026, Financial Results, Revenue Growth, International Exports, Pure Sunfarms, Adjusted EBITDA, SEC Filing, 10-Q, US Cannabis, Canadian Cannabis, Netherlands Cannabis, CBD Products